Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04545060 · ClinicalTrials.gov registry record · Phase 2
VIR-7831 for the Early Treatment of COVID-19 in Outpatients
A Phase 2 study, sponsored by Vir Biotechnology.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,057
- Enrollment target
NCT04545060: Completed Phase 2 study, sponsored by Vir Biotechnology.
NCT04545060 is a Phase 2 study that has completed, run by Vir Biotechnology. The registered enrollment target is 1,057 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (695% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04545060, a Phase 2 study, has completed, sponsored by Vir Biotechnology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,057 participants
- Enrollment target
Study Summary
This is a phase 2/3 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 or placebo and will be assessed for safety, tolerability, efficacy, and pharmacokinetics.
Primary Outcome
COVID-19 progression defined as hospitalization \>24 hours or death
Interventions
- DRUG Placebo
- BIOLOGICAL VIR-7831 (sotrovimab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,057 participants |
| Start Date | 2020-08-27 |
| Est. Completion | 2021-09-02 |
| Phase | Phase 2 |
What the finished NCT04545060 record still lists
NCT04545060 is an interventional study that assigns participants to a tested intervention. Its 1,057 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (695% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04545060 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04545060 about?
NCT04545060 is a clinical study titled "VIR-7831 for the Early Treatment of COVID-19 in Outpatients". This is a phase 2/3 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 or placebo and will be assessed for safety, tolerability, efficacy, and pharmacokinetics.
What is the current status of trial NCT04545060?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,057 participants. The study started on 2020-08-27. Estimated completion is 2021-09-02.
What interventions are being tested in trial NCT04545060?
The interventions under investigation include: Placebo (DRUG), VIR-7831 (sotrovimab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04545060?
This trial is sponsored by Vir Biotechnology, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04545060's enrollment target sits among peer trials
1,057 24th of 2000 higher than 1,977 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07018869 · 1,057 participants · Phase 3
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
- NCT03588286 · 1,058 participants · NA
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)
- NCT03242642 · 1,056 participants · NA
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
- NCT04372108 · 1,056 participants
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI